Skip to main content

Profile hero

Profile details

About Angela Landry (nee Diveley)

Angela is counsel in our antitrust, competition and trade group and is based in Silicon Valley and Washington, DC, where she advises clients on a range of antitrust law issues, including merger control, corporate compliance programs, and agency advocacy.

She is known for providing pragmatic advice relating to the antitrust aspects of multi-million and multi-billion dollar mergers & acquisitions, including antitrust risk assessment, transaction negotiations, multi-jurisdictional merger control, and advocacy before the Federal Trade Commission (FTC) and US Department of Justice’s Antitrust Division (DOJ). She has extensive expertise guiding clients through in-depth agency investigations, as well as significant experience advising clients on corporate compliance programs. She has experience in a wide range of commercial sectors, including financial services, technology, healthcare, retail, and manufacturing.

Prior to joining Freshfields, Angela served as an Attorney Advisor to an FTC Commissioner, providing counsel on antitrust investigations, enforcement actions, and policy initiatives, which provided her with valuable insight into the agency’s deliberative process and the impacts of US antitrust policy on real-world business practices.

Angela is currently serving as a co-editor of Competition Policy International’s North America column on evolving antitrust issues. She also actively works to foster interest in antitrust law and grow the antitrust bar, serving as a mentor, speaking on career panels at her alma mater, and participating as a judge in the annual Global Antitrust Institute Invitational, which is the only moot court competition dedicated exclusively to antitrust law.

Recent work

Angela's experience includes advising:

  • Sonoco on its $3.9bn acquisition of Eviosys.
  • Zymergen on its $300 million sale to Ginkgo Bioworks—the first-ever sale of a publicly-listed public benefit corporation.
  • Aerojet Rocketdyne on its proposed $4.4bn acquisition by Lockheed Martin.
  • London Stock Exchange Group on the US and global merger control aspects of its $27bn deal to acquire Refinitiv, which was allowed to close unconditionally in the US.
  • Johnson & Johnson in connection with its proposed acquisition of TachoSil, a hemostatic patch for surgical bleeding control.
  • Continental Ag on its acquisition of Veyance Technologies Inc. from Carlyle Group.
  • Maersk on the proposed $1bn sale of its refrigerated container business to China International Marine Containers.
  • Stanley Black & Decker on the $3.2bn sale of its global electronic security solutions healthcare solutions businesses to Securitas AB.



  • JD, cum laude, George Mason University School of Law 2012
  • BA, University of California-San Diego 2007


  • Admitted to practice in California and the District of Columbia